Leerink Partnrs Forecasts Oculis' Q2 Earnings (NASDAQ:OCS)

Oculis Holding AG (NASDAQ:OCS - Free Report) - Investment analysts at Leerink Partnrs cut their Q2 2025 earnings per share estimates for Oculis in a research note issued on Wednesday, June 4th. Leerink Partnrs analyst M. Goodman now expects that the company will earn ($0.50) per share for the quarter, down from their prior estimate of ($0.48). The consensus estimate for Oculis' current full-year earnings is ($2.09) per share. Leerink Partnrs also issued estimates for Oculis' Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.65) EPS, FY2025 earnings at ($2.51) EPS, FY2026 earnings at ($2.26) EPS, FY2027 earnings at ($3.49) EPS, FY2028 earnings at ($2.20) EPS and FY2029 earnings at $0.43 EPS.

Oculis (NASDAQ:OCS - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.26). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. The company had revenue of $0.32 million for the quarter, compared to the consensus estimate of $0.22 million.

Several other brokerages also recently weighed in on OCS. Chardan Capital raised their price target on Oculis from $28.00 to $33.00 and gave the company a "buy" rating in a report on Friday, May 9th. HC Wainwright raised their price objective on shares of Oculis from $29.00 to $32.00 and gave the company a "buy" rating in a research note on Thursday, April 17th. Finally, Robert W. Baird raised their price target on shares of Oculis from $37.00 to $41.00 and gave the company an "outperform" rating in a research report on Thursday, March 13th.

Oculis Price Performance

Shares of NASDAQ:OCS opened at $19.92 on Monday. Oculis has a 1-year low of $10.79 and a 1-year high of $23.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02. The business has a fifty day moving average price of $17.91 and a 200-day moving average price of $18.76. The company has a market capitalization of $869.75 million, a PE ratio of -10.32 and a beta of 0.35.

Institutional Trading of Oculis

Large investors have recently modified their holdings of the company. Citadel Advisors LLC bought a new stake in shares of Oculis in the fourth quarter worth $389,000. Geode Capital Management LLC grew its stake in shares of Oculis by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock valued at $284,000 after purchasing an additional 1,800 shares during the period. XTX Topco Ltd bought a new stake in shares of Oculis during the 4th quarter valued at about $225,000. Bellevue Group AG bought a new stake in shares of Oculis during the 4th quarter valued at about $170,000. Finally, Alyeska Investment Group L.P. bought a new stake in Oculis during the first quarter valued at approximately $2,499,000. Institutional investors own 22.30% of the company's stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.